Member Area

Farmavita.Net - Pharmaceutical Licensing Network

Wednesday
Mar 17th
Home arrow Farmavita.Net Journal
Farmavita.Net Journal
Print E-mail
Market Report

datamonitor_logo.gif

Diabetes to the fore as generics hit primary care markets

Datamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2017. A large and diverse development pipeline will provide a number of new blockbuster drugs but the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market only growing by 0.9% in the seven major markets.

Read more...
 
Print E-mail
Market Report

business-insights-logo.gif

Commercial strategies in cardiovascular and metabolic diseases-successful market positioning at company and brand level becomes paramount

Datamonitor expects commercial strategies in the cardiovascular and metabolic markets to become increasingly important as the markets mature. The report details strategies used by pharmaceutical companies to capture market share, to differentiate brands from the competition, for revenue maximization and for the defense of brand revenues from generic competition.

Read more...
 
Print E-mail
Press Release

datamonitor_logo.gif

Prasugrel: a flawed approval?

On July 10, 2009, the FDA approved Effient (prasugrel) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention. However, the approval has surprised many physicians as prasugrel has had a tortuous clinical development program, with important questions raised over its clinical benefits and the trial design.

Read more...
 
Print E-mail
Market Report

business-insights-logo.gif

Technology Transfer Strategies: Maximizing the returns from new technologies

Technology transfer is a long-established part of early-stage research within the pharmaceutical and biotechnology industries. Although technology transfer offices have traditionally been associated with inefficiency and a lack of commercial judgment, recent trends have shown improvements in staffing, expertise and service levels.

Read more...
 
Print E-mail
Company Report

business-insights-logo.gif

Evolving Trends in Biopharmaceutical Licensing: Deal assessments, drivers and resistors

‘Evolving Trends in Biopharmaceutical Licensing' is a report published by Business Insights that provides a detailed analysis of licensing strategies in the biopharmaceutical industry over the 2001-08 period. This report examines the growth of the biopharmaceutical industry, deal-making trend data, drivers and challenges facing biopharmaceutical licensing, and profiles of biopharmaceutical licensing among leading companies.

Read more...
 
Print E-mail
Market Report

business-insights-logo.gif

The Autoimmune Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities

Autoimmune disorders have been one of the most prominent growth segments in the pharma industry over the last decade. A growing patient population and high levels of unmet need are the main drivers of market growth, and novel biologics are increasingly helping to fulfill patient need, with their high cost helping to drive market sales.

Read more...
 
Print E-mail
Company Report

business-insights-logo.gif

The Top 10 Contract Research Organizations:Positioning, performance and SWOT analyses

Cost containment and regulatory pressures within the pharma industry are driving R&D outsourcing across the globe. Clinical obstacles to approval have become more significant due to the growing availability of existing generic treatments, and the trend to adopt Health Economics Outcomes Research (HEOR) assessments is increasing the complexity of clinical research.

Read more...
 
Print E-mail
Market Report

business-insights-logo.gif

Market developments, outsourcing hotspots and growth strategies

This report aims to identify the hotspots and profile the leading players in the global pharmaceutical contract manufacturing market.

Read more...
 
Print E-mail
Open Innovation

How pharmaceutical and biotech industry could  survive and thrive in a world where new media technology creates our lives and our future?

Infinite NetSocial networks may shape the future of pharmaceutical and biotechnology industry

We live in a time of mass media. The internet and computers of all shapes and sizes could soon replace the written word, television and radio. We pay our bills through internet-banking. We read newspapers on their internet sites. We make new acquaintances through virtual networks.

Read more...
 
Print E-mail
Market Report

business-insights-logo.gif

New technologies, growth opportunities, and the future market outlook

‘Innovations in In-Vitro Diagnostics' provides an in-depth analysis of emerging opportunities and potential clinical advances across the diagnostics markets of coronary heart disease, heart failure, bacterial infections and viral infections.

Read more...
 
Print E-mail
Market Report

business-insights-logo.gif

Accelerating Lead Generation: Emerging technologies and strategies

This report provides an in-depth examination of state-of-the-art technologies for lead generation.

Read more...
 
Print E-mail
Market Report

business-insights-logo.gif

The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses

Biologics continue to outperform the global pharma market, driven by premium priced therapies for conditions that cannot be managed by conventional drugs. The rapid penetration of novel biologics and the gradual expiry of their patents will create significant market opportunities for biosimilars developers through to 2016.

Read more...
 
Print E-mail
Company Report

business-insights-logo.gif

Managing cost containment and safeguarding productivity

For several years, drug developers have been under intense pressure to introduce new products in an environment of escalating R&D costs, blockbuster patent expiration and resulting generic competition, increasingly complex science, heightened regulatory scrutiny, and other pressures. Now, however, the global economic meltdown has added new imperatives for drug makers to cut costs.

Read more...
 
Print E-mail
Market Report

business-insights-logo.gif

Maximizing opportunities towards achieving clinical success

For the last few years the biggest pharma companies have started to bring new technologies for drug safety prediction into the discovery phases of research. This report will describe these technologies, their place in the drug discovery and development paradigm and their value for improving drug safety.

Read more...
 
Print E-mail
Market Report

datamonitor_logo.gif

Forecast Analysis

The high cost and utilization of biologic drugs, coupled to the growing need to curb pharmaceutical expenditure, provides considerable momentum to the emerging biosimilars market. With a biosimilar approval pathway in place in Europe and Japan, and imminently in the US, Datamonitor expects payer pressure to drive biosimilar uptake, particularly in Germany, the US, and the UK.

Read more...
 
Print E-mail
Market Report

datamonitor_logo.gif

Physician perception of biologics in autoimmune disease - Targeted detailing is the key to success

Factors influencing a prescribing decision can diverge from clinical facts. In the highly competitive autoimmune area, misconceptions and physician habits can result in loss of sales. Targeted detailing of specialist physicians, differentiating by indications is the key to success. Datamonitor has surveyed gastroenterologists, rheumatologists and dermatologists on attribute and brand perceptions

Read more...
 
Print E-mail
Market Report

datamonitor_logo.gif

New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency

With industry consolidation, the economic downturn, and an increasing threat from generics, pharma companies are coming under greater pressure to fill their pipelines with innovative drugs. However, despite the costs and risks involved in drug development, the pharma industry is finding new ways to streamline the R&D process in an effort to increase efficiency and output.

Read more...
 
Print E-mail
Press Release

datamonitor_logo.gif

Drug repositioning strategies: a different approach to innovation

With increased investment in R&D largely failing to fill drug development pipelines, the pharma industry is looking to get more bang for its R&D buck by generating some return out of failed drug candidates and extra return out of others. Drug re-positioning has become a key strategy for pharmaceutical groups, and according to Datamonitor, this approach is set to become more frequently employed.

Read more...
 
Print E-mail
Product Report

datamonitor_logo.gif

Forecast Analysis

The high cost and utilization of biologic drugs, coupled to the growing need to curb pharmaceutical expenditure, provides considerable momentum to the emerging biosimilars market. With a biosimilar approval pathway in place in Europe and Japan, and imminently in the US, Datamonitor expects payer pressure to drive biosimilar uptake, particularly in Germany, the US, and the UK.

Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Results 134 - 152 of 573
Advertisement
 

Featured Video

More videos ...

3D Content Cloud

Featured Partners

farmavita_research-store.gif
top-20-cancer-therapy-brand.jpg
generics-growth-strategies2.gif
sfe_eu10_150x150_v2.gif 
mddexeceu10_150x150_v1.gif
discovery2010_150x150.gif
150x150_salesonco-master.gif
pharma_omaeu10_150x150_v2.gif
risksharingnextlevel.gif 
arriello-150x150.gif 
150x150_ceepr3_master.gif 
pharmabrand2010_150x150.gif
 

Login to Farmavita.Net

membership is FREE

Follow us on:

bpe_oglas.gif




Join our LinkedIn Group

BabelFish Translator




Click Flag for Translation

Who's Online

We have 17 guests online

Farmavita.Net RSS News


Products

Click to Products

JobLine

Click here ...Post a Job for Free

Reports

Click to Reports

Events

Click to Events

CRAMS

Click to CRAMS